Skip to main content
Log in

Interstitielle Zystitis

Aktuelle Aspekte in der Diagnostik und Therapie

Interstitial cystitis

New aspects in diagnosis and therapy

  • Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Urologe, Ausgabe A Aims and scope Submit manuscript

Zusammenfassung

Die interstitielle Zystitis (IC) ist eine chronisches, heterogenes Syndrom, das mit den klassischen Symptomen „Nykturie, Pollakisurie und Blasenschmerzen“ einhergeht. Populationsstudien zeigen ansteigende Prävalenz- und Inzidenzraten. Von den unterschiedlichen Hypothesen zur Pathogenese und Ätiologie werden die der epithelialen Dysfunktion und der neurourothelialen Wechselwirkung am häufigsten zur Erklärung genutzt. Es empfiehlt sich eine individuelle und flexible Anwendung der offiziellen Diagnosekriterien des NIDDK (National Institute of Diabetes, Digestive and Kidney Disease), um gut therapierbare Frühformen nicht zu übersehen. Da ein pathognomonischer Marker noch fehlt, beruht die Diagnose v. a. auf klinischen Befunden und dem Ausschluss von Differenzialdiagnosen. Blasenspiegelung und Probebiopsie sind nicht beweisend, machen die Diagnose jedoch wahrscheinlicher und können wichtige Informationen über den Ausprägungsgrad, auch in Hinblick auf eine angepasste Therapie, liefern. Die elektromotorische Medikamentenapplikation (EMDA) in der Instillationstherapie hat in den letzten Jahren die Erfolgsraten der konservativen Therapie deutlich verbessert.

Abstract

Interstitial cystitis is a chronic, heterogeneous syndrome that is characterized by the classic symptoms of bladder pain, nycturia, and pollakiuria. Population studies have shown an increase in prevalence and incidence. Different hypotheses exist about the etiology and pathogenesis. Epithelial dysfunction and neuro-urothelial interaction are the most frequently used causal models. Utilization of the official diagnosis criteria of the NIDDK (National Institute of Diabetes, Digestive and Kidney Disease) should be flexible and individual in order not to overlook early forms of IC. Since there is no pathognomonic marker, diagnosis of IC is a combination of typical patient history and exclusion of differential diagnoses. Cystoscopy and biopsies are not specific; however, they can provide useful information on extent and aid in treatment choice. The effectiveness of conservative therapy has been increased by using electromotive drug administration (EMDA) in instillation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Bouchelouche K, Nordling J, Hald T, Bouchelouche P (2001) The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of IC. J Urol 166: 1734–1737

    Google Scholar 

  2. Keay S, Zhang CO, Chai T, Warren J, Koch K, Grkovic D, Colville H, Alexander R (2003) Antiproliferative factor, heparin-binding epidermal growth factor and epidermal growth factor in men with interstitial cystitis versus chronic pelvic pain syndrome. Urology 63 (1): 22–26

    Google Scholar 

  3. Lippilahti M, Tammela TLJ, Huhtala H, Auvinen A (2002) Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urol 168: 139

    Google Scholar 

  4. Loch A, Stein U, Loch T, Stöckle M (2004) Histopathological patterns and distribution of mast cells and nerve fibres in interstitial cystitis and its implications for surgery therapy. Eur Urol Suppl 3 (2), 203A

  5. Marshall K (2003) Interstitial cystitis: understanding the syndrome. Alternative Med Rev 8 (4): 426–437

    Google Scholar 

  6. Mattox TF, Facog MD (2004) Interstitial cystitis in adolescents and children: a review. J Pediatr Adolesc Gynecol 17: 7–11

    Article  CAS  PubMed  Google Scholar 

  7. Oberpenning F, van Ophoven A, Hertle L (2002) Praktische Hinweise zur Diagnostik. In: Interstitielle Cystitis, The State of the Art. ICA Deutschland e.V., Biermann, Köln, S 23–28

  8. O’Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J (1997) The interstital cystitis symptom index and problem index. Urology A 49 (5a): 58–63

    Article  Google Scholar 

  9. Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G (1998) The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol 159: 1862–1867

    Google Scholar 

  10. Porru D, Politanò R, Gerardini M et al. (2004) Different clinical presentation of interstitial cystitis syndrome. Int Urogynecol J Pelvic Floor Dysfunct 15: 198–202

    Article  CAS  PubMed  Google Scholar 

  11. Roberts RO, Bergstralh EJ, Bass SE, Lightner DJ, Lieber MM, Jakob SJ (2003) Incidence of physician-diagnosed interstitial cystitis in Olmst County: a community-based study. BJU Int 91 (3): 181–185

    Article  CAS  PubMed  Google Scholar 

  12. Sairanen J, Forsell T, Ruutu M (2004) Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporin A. J Urol 171 (6 Pt 1): 2138–2141

    Google Scholar 

  13. Sun Y, Chai TC (2004) Up-Regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol 171 (1): 448–452

    Google Scholar 

  14. u Zhang CO, Li ZL, Shoenfelt JL et al. (2003) Comparison of APF activity and epitheal growth factor level in urine from Chinese, African-American, and white American patients with interstitial cystitis. Urology 61 (5): 897–901

    Google Scholar 

  15. Warren JW, Jackson TL, Langenberg P, Meyers DJ, XU J (2004) Prevalence of interstitial cystitis in first-degree relatives of patients with interstitial cystitis. Urology 63 (1): 17–21

    Article  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Loch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loch, A., Stein, U. Interstitielle Zystitis. Urologe [A] 43, 1135–1146 (2004). https://doi.org/10.1007/s00120-004-0664-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-004-0664-9

Schlüsselwörter

Keywords

Navigation